Lataa...
5PSQ-064 Use of sorafenib in cellular hepatocarcinoma in routine clinical practice
BACKGROUND: Sorafenib is a multikinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). In clinical trials sorafenib treatment resulted in a median overall survival of 9.2 months and a median time to progression of 5.5 months (SHARP study). PURPOSE: To describe the results of...
Tallennettuna:
| Julkaisussa: | Eur J Hosp Pharm |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Group
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535212/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.418 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|